Skip to main content
SpringerLink
Log in

Perspectives for the future

  • Originals
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

Abstract

The pathophysiology of sepsis and septic shock is extremely complex and ultimately involves every physiological pathway. The initiating event is the entrance of endotoxin or similar substances into the blood which initiates the release of multiple mediators. These are designed to react locally and to protect the organism. Their constant release, however, sets in motion up- and down regulations, ultimately resulting in “metabolic anarchy”. Tumor necrosis factora and other cytokines trigger several systems, especially coagulation to yield DIC, and the complement system. Many treatment modalities have been developed, most recently those which substitute inhibitors of various systems. Antithrombin III concentrates and potentially protein C concentrates are designed to arrest DIC. C1-esterase inhibitor concentrates should intercept the activation of the complement system and the contact phase of coagulation and its relationship to kinin generation. Even newer approaches entail antibodies to tumor necrosis factora or endotoxin itself. The complex process of sepsis will undoubtedly require a multifaceted therapeutic approach.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Parillo JE (1989) Septic shock in humans: clinical evaluation, pathophysiology, and therapeutic approach. In: Shoemaker WC, Thompson WL, Holbrook P (eds) Textbook of critical care, 2nd edn. Saunders, Philadelphia, pp 1006–1023

    Google Scholar 

  2. Parker MM, Parillo JE (1983) Septic shock: hemodynamics and pathogenesis. JAMA 250:3324–3327

    Google Scholar 

  3. Bone RC (1991) The pathogenesis of sepsis. Ann Intern Med 115:457–469

    Google Scholar 

  4. Tracy KJ, Vlassara H, Cerami A (1989) Cachectin/tumour necrosis factor. Lancet I:1122–1126

    Google Scholar 

  5. Johnston BR (1988) Monocytes and macrophages. N Engl J Med 318:747–752

    Google Scholar 

  6. Harris RL, Musher DM, Bloom K, Gathe J, Rice L, Sugarman B, Williams TW Jr, Young EJ (1987) Manifestations of sepsis. Arch Intern Med 147:1895–1906

    Google Scholar 

  7. Nawroth PP, Stern DM (1986) Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 163:740–745

    Google Scholar 

  8. Gamble JR, Harlan JM, Klebanoff SJ, Vadas MA (1985) Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci USA 82:8667–8671

    Google Scholar 

  9. Beutler B, Cerami A (1987) Cachectin: more than a tumor necrosis factor. N Engl J Med 316:379–385

    Google Scholar 

  10. Braquet P, Touqui L, Shen TY, Vargafting BB (1987) Perspectives in platelet-activating factor research. Pharmacol Rev 39:97–145

    Google Scholar 

  11. Petrak RA, Balk RA, Bone RC (1989) Prostaglandins, cyclo-oxygenase inhibitors, and thromboxane synthetase inhibitors in the pathogenesis of multiple systems organ failure. Crit Care Clin 5:303–314

    Google Scholar 

  12. Jacobs RF, Tabor DR (1989) Immune cellular interactions during sepsis and septic injury. Crit Care Clin 5:9–26

    Google Scholar 

  13. Dinarello CA, Mier JW (1987) Lymphokines. N Engl J Med 317:940–945

    Google Scholar 

  14. Lewis RA, Austen KF, Soberman RJ (1990) Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 323:645–655

    Google Scholar 

  15. Robinson RA, Worfolk L, Tracy PB (1992) Endotoxin enhances the expression of monocyte prothrombinase activity. Blood 79:406–416

    Google Scholar 

  16. Griffin HJ, Cochrane CG (1979) Recent advances in the understanding of the contact activation reactions. Semin Thromb Hemost 5:254–273

    Google Scholar 

  17. Müller-Berghaus G (1989) Pathophysiology and biochemical events in disseminated intravascular coagulation: Dysregulation of procoagulant and anticoagulant pathways. Semin Thromb Hemost 15:58–87

    Google Scholar 

  18. Malik AB, Fenton II JW (1992) Thrombin-mediated increase in vascular endothelial permeability. Semin Thromb Hemost 18:193–199

    Google Scholar 

  19. Robbins KC (1982) Fibrinolysis. In: Kwaan HE, Bowie EJW (eds) Thrombosis. Saunders, Philadelphia, pp 23–28

    Google Scholar 

  20. Fine DP (1985) Role of complement in endotoxin shock. In: Hinshaw LB (ed) Handbook of endotoxin, vol. 2. Elsevier, Amsterdam, p 129–144

    Google Scholar 

  21. Tonnesen MG, Smedly LA, Henson PM (1984) Neutrophil-endothelial cell interactions. Modulation of neutrophil adhesiveness induced by complement fragment C5a and C5a des arg and formylmethionyl-leucyl-phenylalanine in vitro. J Clin Invest 74:1581–1592

    Google Scholar 

  22. Smedly LA, Tonnesen MG, Sandhaus RA, Haslett C, Guthrie LA, Johnston RB Jr, Henson PM, Worthen GS (1986) Neutrophilmediated injury to endothelial cells. Enhancement by endotoxin and essential role of neutrophil elastase. J Clin Invest 77:1233–1243

    Google Scholar 

  23. Worthen GS, Haslett C, Smedly L, Rees A, Gumbay RS, Henson J, Henson PM (1986) Lung vascular injury induced by chemotactic factors: enhancement by bacterial endotoxins. Fed Proc 47:7–12

    Google Scholar 

  24. Goodman MG, Chenoweth DE, Weigle WO (1982) Induction of interleukin 1 secretion and enhancement of humoral immunity by binding of human C5a to macrophage surface C5a receptors. J Exp Med 156:912–917

    Google Scholar 

  25. Silverberg M, Nicoll JE, Kaplan AP (1980) The mechanism by which the light chain of cleaved HMW-kininogen augments the activation of prekallikrein, factor XI and Hageman factor. Thromb Res 20:173–178

    Google Scholar 

  26. Wiggins RC, Giclas PC, Henson PM (1981) Chemotactic activity generated from the fifth component of complement by plasma kallikrein of rabbit. J Exp Med 153:1391–1399

    Google Scholar 

  27. Thrompson RE, Mandle R, Kaplan AP (1978) Characterization of high molecular weight kininogen. J Exp Med 147:488–496

    Google Scholar 

  28. Reynolds HN, Haupt MT, Thill-Baharozian MC, Carlson RW (1988) Impact of critical care physician staffing on patients with septic shock in a university hospital medical intensive care unit. JAMA 260:3446–3450

    Google Scholar 

  29. Bryan CS, Reynolds KL, Bramer ER (1983) Analysis of 1,186 episodes of gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy. Rev Infect Dis 5:629–638

    Google Scholar 

  30. Desjars P, Pinaud M, Potel G, Tasseau F, Touze MD (1987) Reversal of intractable septic shock with norepinephrine therapy in human septic shock. Crit Care Med 15:134–137

    Google Scholar 

  31. Sprung CL, Caralis PV, Marcial E, Pierce M, Gebhard MA, Long WM, Duncan RC, Tendler MD, Karpf M (1984) The effects of high-dose corticosteroids in patients with septic shock: a prospective, controlled study. N Engl J Med 311:1137–1143

    Google Scholar 

  32. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA (1987) A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317:653–658

    Google Scholar 

  33. Hinshaw L, Peduzzi P, Young E (1987) Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. The Veterans Administration Systemic Sepsis Cooperative Study Group. N Engl J Med 317:659–665

    Google Scholar 

  34. Ognibene FP (1990) Management of septic shock. In: Parillo JE (moderator) Septic shock in humans: Advances in the understanding of pathogenesis, cardiovascular dysfunction and therapy. Ann Intern Med 113:227–242

    Google Scholar 

  35. Mosher DF (1980) Fibronectin. Prog Hemost Thromb 5:111–151

    Google Scholar 

  36. Saba TM, Jaffe E (1980) Plasma fibronectin (opsonic glycoprotein): Its snythesis by vascular endothelial cells and role in cardiopulmonary integrity after trauma as related to reticuloendothelial function. Am J Med 68:577–594

    Google Scholar 

  37. Grossman JE (1987) Plasma fibronectin and fibronectin therapy in sepsis and critical illness. Rev Infect Dis 9:[Suppl 4] S420-S430

    Google Scholar 

  38. Rosenberg RD (1975) Action and interaction of antithrombin and heparin. N Engl J Med 16:146–152

    Google Scholar 

  39. Oguma Y, Sakuragawa N, Maki M, Hasegawa H, Nakagawa M for a Research Group of FR860 on DIC in Japan (1990) Treatment of disseminated intravascular coagulation with low molecular weight heparin. Semin Thromb Hemost 16:[Suppl 3]:4–40

    Google Scholar 

  40. Markwardt F (1991) The comeback of hirudin as an antithrombotic agent. Semin Thromb Hemost 17:79–82

    Google Scholar 

  41. Mammen EF, Miyakawa T, Phillips TF, Assarian GS, Brown JM, Murano G (1985) Human antithrombin concentrates and experimental disseminated intravascular coagulation. Semin Thromb Hemost 11:373–383

    Google Scholar 

  42. Taylor FB, Emerson TE, Jordan R, Chang AK, Blick KE (1988) Antithrombin-III prevents the lethal effects ofEscherichia coli infusion in baboons. Cire Shock 26:227–235

    Google Scholar 

  43. Seitz R, Wolf M, Egbring R, Havemann K (1989) The disturbances of hemostasis in septic shock: role of neutrophil elastase and thrombin, effects of antithrombin III and plasma substitution. Eur J Haematol 43:22–28

    Google Scholar 

  44. Okamoto K, Takaki A, Takeda S, Katoh H, Ohsato K (1992) Coagulopathy in disseminated intravascular coagulation due to abdominal sepsis: Determination of prothrombin fragment 1+2 and other markers. Haemostasis 22:17–24

    Google Scholar 

  45. Bone RC (1992) Sepsis and coagulation: an important link. Chest 191:594–596

    Google Scholar 

  46. Wilson RF, Farag AM, Mammen EF, Fujii Y (1989) Sepsis and antithrombin III, prekallikrein, and fibronectin levels in surgical patients. Am Surg 7:450–456

    Google Scholar 

  47. Vinazzer H (1989) Therapeutic use of antithrombin III in shock and disseminated intravascular coagulation. Semin Thromb Hemost 15:347–352

    Google Scholar 

  48. Blanco A, Guisasola JA, Solis P, Bechiller R, Gonzalez H (1990) Fibronectin in meningococcal sepsis. Correlation with antithrombin III and protein C. Acta Paediatr Scand 79:73–76

    Google Scholar 

  49. Taylor FB, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE (1987) Protein C prevents the coagulopathic and lethal effects ofEscherichia coli infusion in the baboon. J Clin Invest 79:918–925

    Google Scholar 

  50. Krishnamurti C, Young GD, Barr CF, Colleton CA, Alving BM (1991) Enhancement of tissue plasminogen activator-induced fibrinolysis by activated protein C in endotoxin-treated rabbits. J Lab Clin Med 118:523–530

    Google Scholar 

  51. Bork K, Witzke G (1989) Long-term prophylaxis with C1-inhibitor (C1-INH) concentrates in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency. J Allergy Clin Immunol 83:677–682

    Google Scholar 

  52. Mammen EF (1990) Contact activation: the interaction of clotting, fibrinolytic, kinin and complement systems. Biomed Prog 2:31–34

    Google Scholar 

  53. Dosquet C, Wautier JL (1992) Facteurs de contact and cours des états septiques graves. Presse Méd 21:210–215

    Google Scholar 

  54. Hack CE, Voerman HJ, Eisele B, Keinecke H-O, Nuijens JH, Eerenberg AJM, Oglivie A, van Schijnder RJM, Delvos U, Thijs LG (1992) C1-esterase inhibitor substitution in sepsis. Lancet I:378

    Google Scholar 

  55. Nürnberger W, Görel U, Stannigel H, Eisele B, Janssen A, Delvos U (1992) C1-inhibitor concentrate for sepsis-related capillary leak syndrome. Lancet I:990

    Google Scholar 

  56. Greenman RL, Schein RMH, Martin MA, Wenzel RP, MacIntyre NR, Emanuel G, Chmel H, Kohler RB, McCarthy M, Plouffe J (1991) A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 266:1097–1102

    Google Scholar 

  57. Teng NN, Kaplan HS, Hebert JM, Moore C, Douglas H, Wunderlich A, Brande AI (1985) Protection against Gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc Natl Acad Sci USA 82:1790–1794

    Google Scholar 

  58. Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas H, Brande AI (1982) Treatment of gram-negative bacteremia and shock with human antiserum to a mutant ofEscherichia coli. N Engl J Med 307:1225–1230

    Google Scholar 

  59. Warren HS, Danner RL, Munford RS (1992) Sounding board: antiendotoxin monoclonal antibodies. N Engl J Med 326:1153–1157

    Google Scholar 

  60. Beutler B, Milsark IW, Cerami AC (1985) Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effects of endotoxin. Science 229:869–871

    Google Scholar 

  61. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A (1987) Anti-cachectin/TNF monocloncal antibodies prevent septic shock during lethal bacteraemia. Nature 330:662–664

    Google Scholar 

  62. Opal SM, Cross AS, Kelly NM, Sadoff JC, Bodmer MW, Palardy JE, Victor GH (1990) Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection withPseudomonas aeruginosa. J Infect Dis 161:1148–1152

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Pathology, Physiology, Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI, USA

    E. F. Mammen

  2. C. S. Mott Center, 275 East Hancock, 48201, Detroit, MI, USA

    E. F. Mammen

Authors
  1. E. F. Mammen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mammen, E.F. Perspectives for the future. Intensive Care Med 19 (Suppl 1), S29–S34 (1993). https://doi.org/10.1007/BF01738947

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01738947

Key words

Search

Navigation